Our Passionate Industry Leaders

Kevin Xu is currently serving as the Chairman & CEO of ClinChoice. Previously, Kevin was a Managing Director at Goldman Sachs, where he built and led the firm’s Asia-Pacific Healthcare & Life Science Investing business for over 15 years. During his tenure, he directed high-impact investments across biotech, pharma, medtech, CROs/CDMOs, and digital health, backing industry-leading innovators.

Kevin holds an MSc in Neuroscience and Clinical Psychology from King’s College London, a Master of Finance from the University of Cambridge, and a B.S. from the University of Maryland. He also serves as the Queens’ Alumni Ambassador for Strategic Partnerships at the University of Cambridge.

Dr. Dyson serves as President, Head of Clinical Operations, leading the ClinChoice team committed to delivering exceptional clinical development services and flexible support to pharmaceutical, medical device and consumer health clients.

Kerry has over 25 years of experience in clinical research within the pharmaceutical and CRO sectors. During this time, he has worked at all levels and across operational and commercial functions within the industry. Within each role Dr. Dyson enjoyed key responsibilities for providing strategic input to the successful growth and development of the company. Most recently, Kerry served as Chief Operating Officer of CROMSOURCE, leading teams delivering clinical operations, biometrics, regulatory, medical and pharmacovigilance services.

Dr. Dyson holds a PhD in Applied Physiology from Leeds Metropolitan University and MSc in Kinesiology from McMaster University. He has authored numerous academic publications and written various articles on clinical research topics.

Tiepu Liu, MD, PhD, is President, Head of Biometrics at ClinChoice. He leads goal setting and strategic plans, and manages organizational structure and operational standards and process. He supports experienced clinical development teams specialized in data management, biostatistics and programming, and data science and technology to provide high quality and efficient services to global biopharmaceutical clients.

Dr. Liu served as a Biostatistician and Epidemiologist at the UAB Comprehensive Cancer Center and led a Biostatistics and Epidemiology group at the University of Cincinnati. In his industry career, he has served as Director of Biostatistics at PPD, Executive Director of Statistics and Data Management at UBC, and Senior Director of Biostatistics at Graceway Pharmaceuticals and The Medicines Company.

Dr. Liu has published over 100 scientific papers. He has worked with numerous Data Monitoring Committees (DMCs) in various capacities. Dr. Liu has led numerous clinical development programs in various therapeutic areas. He served as core lead in gaining global approval and successful commercialization of Arestin (minocycline), Zyclara (imiquimod), and Kengreal (cangrelor) interacting with various regulatory agencies, including FDA, EMA, PMDA, and NMPA.

Dr. Liu received his doctoral degree in Biostatistics and Epidemiology from the University of Alabama at Birmingham (UAB) after completing Medical and Public Health training at Tongji Medical University, China.

Christy Shen is the Global CFO of ClinChoice, overseeing global financials and corporate related initiatives.  She has over 25 years of financial management experience in healthcare industry and FMCG industry, within which she spent recent 10 years in CRO sector.

Prior joining ClinChoice, Christy was the Greater China Finance Head of Quintiles. Earlier, Christy had worked in Global Pharmaceutical companies of GSK and Sanofi during which she managed Greater China FP&A and Business Unit finance partnership. Christy started her career in Proctor&Gamble as management trainee and developed her financial management capabilities in various roles.  

Christy received her Bachelor degree in South China University of Technology, majored in Finance & Accounting. She received her Master degree of MBA in Peking University. Christy is Fellow of the Chartered Institute of Management Accountants, Chartered Global Management Accountant.

John D. Balian, MD, is the CEO International ClinChoice Inc; Board Director; Co-Founder. In February 2016, he founded the consulting firm MediVista, focusing on development of healthcare and IT companies and transformative technologies. Previously, he was a senior executive at Johnson & Johnson, where he served as Chief Medical Officer of the Johnson & Johnson Family of Consumer Companies, leading Medical, Clinical, Regulatory, Medical Safety, Toxicology, and related functions. In April 2014, Regional R&D was added to his remit and his title became Chief R&D Operations Officer.

Dr. Balian joined Johnson & Johnson from Pfizer Inc, where he was Senior Vice President, Worldwide Safety & Regulatory Operations. He led efforts to capitalize on the immense data streams Pfizer collects to gain new insights into patient needs and find new opportunities to serve them better. He launched and successfully executed a complete transformation of the organization’s structure, practices and strategies to address performance and regulatory challenges facing the company.

In 10 years at Pfizer, Dr. Balian held numerous leadership positions, originally joining as an Associate Director in Drug Safety before soon becoming Vice President and Global Head for Clinical Safety and Risk Management. In 2003, he was appointed VP in Development Operations, leading a multi-functional organization responsible for Pfizer’s sourcing strategies, capacity planning, clinical trials conduct and allocation, patient recruitment, performance measures and business/operational support for all clinical trials.

He also served at Bristol-Myers Squibb, leading the Global Pharmacovigilance & Epidemiology group and a Medical Affairs group focusing on mature brands. Among the many innovative methodologies he introduced was a BMS global operations center for pharmacovigilance in Chennai, India, an industry first.

Previously, Dr. Balian worked for the U.S. Food & Drug Administration, first as a Medical Reviewer for neuropharmacology products, and then as an Associate Director in the Office of Clinical Pharmacology and Biopharmaceutics. Widely published in scientific journals, he is also a published novelist. He earned his B.A. degree from Columbia University and his M.D. degree from Tufts University School of Medicine.

A co-founder of iMEDGlobal (a ClinChoice Company), Mahesh has more than 27 years of industry experience including 14 years of designing and implementing global software solutions in the healthcare and pharmaceutical domains.

His most recent experience includes tenures as CEO iMEDGlobal Inc – a KPO company providing services in the life sciences space. He was instrumental in taking the company from inception to a 500+ member strong company. He was also the Global Head, Product Development at ArisGlobal, India, and Engineering Manager at WYSE, India. He has also worked as a consultant, with DSA to help develop its IT service offering for the life sciences industry and worked on the Triage XML Intake system. Prior to the Life Sciences space, Mahesh has worked extensively in the Banking and Enterprise domain designing and developing solutions.

Mahesh has a bachelor’s degree in Instrumentation Engineering from Bangalore University, India.

Somodipto Basu is the International Head of EMEA and Information Technology at ClinChoice. In this role, Somo heads up ClinChoice’s operations in the EMEA region and leads the Global IT and Technology Innovation practice. Somo is focused on bolstering ClinChoice’s deep life sciences expertise with the power of next-gen technologies to unlock new insights to improve compliance and efficiencies.

Since 2013, Somo has been responsible for client engagement and business management, expanding ClinChoice’s presence in Europe. As a technology evangelist, Somo has been at the forefront of developing lightweight and enterprise solutions for the life sciences domain.

Previously, Somo was part of the start-up leadership team at Synowledge LLC (now Qinesca), where he was instrumental in establishing the technology business unit and laying the foundation for its accelerated growth. Before Synowledge, Somo spent a decade with IBM managing key accounts mainly from the life sciences domain. Prior to IBM, he also served as a techno-functional business analyst at Pharmacia (a Pfizer company) and application developer at Reckitt & Colman.

Somo holds a BS degree and an Executive MBA from the Indian Institute of Management (IIM) Bangalore, India.

Jimish Shah, MS, MBA, is the International Head, Medical Affairs, Regulatory and Safety (MARS) at ClinChoice. He provides global leadership and strategic direction to a team of highly talented physicians, doctorates, and life-sciences graduates who are providing comprehensive support to clients for their pharmacovigilance, regulatory and medical affairs need. Mr. Shah is also acting as the Interim International Head of Commercial, responsible for commercial success of the organization. He currently oversees the Sales and Marketing functions to drive business growth and market share.

Mr. Shah has over 20 years of experience in academia, consulting, and the life-sciences industry. Mr. Shah started his career in the life-sciences industry by working with Novartis as a Medical Writer. Later, Mr. Shah worked with several other biopharmaceutical companies and supported clinical submission for over a dozen products under oncology, cardiovascular, and immunology areas. Mr. Shah also designed tools for automating patient narrative compilation and planning for clinical documents authoring, and implemented process optimization that has resulted in significant cost efficiencies for the organizations.

Mr. Shah earned his BS in Biotechnology from S. P. University (India), M.S. in Clinical Research from Cranfield University (UK) and MBA from the Simon Business School, University of Rochester (USA).

Molly Sang is the International Head of Finance of ClinChoice Inc., where she brings over 20 years of extensive experience in audit, accounting, and financial management to the executive team.

As International Head of Finance, Molly oversees all facets of financial operations and management, including accounting, audit, treasury, and financial planning & analysis. Her journey with ClinChoice started in 2019, and since then, she has played a pivotal role in steering the financial course of the company, ensuring fiscal responsibility, and contributing to the overall success of the organization.

Prior to joining ClinChoice, Molly held key financial positions in multinational pharmaceutical, medical device, and CRO companies, where she successfully led financial teams and managed a broad range of financial responsibilities.

Molly is a Certified Public Accountant with a Master of Business Administration from the University of St. Thomas at Minneapolis, Minnesota, and a Bachelor of Arts from Peking University in China.

Lei Lu, MS, MBA, is the International Head of Business Operations at ClinChoice Inc. She provides leadership for strategies and processes and oversees activities in business operations, including procurement, legal, human resources, and day-to-day administration.

Ms. Lu has over 28 years of combined experience in the biotechnology, pharmaceutical, and CRO industries. Prior to joining ClinChoice, she worked at Merck for 20 years in diverse areas ranging from quality to R&D to global business procurement. Her broad experience allows her to provide oversight of business operations and think strategically with her deep understanding of the technical and business aspects of the pharmaceutical industry.

Ms. Lu has an MBA in finance from Temple University, an MS in Organic Chemistry from Texas Women’s University, and a BS in Chemistry from Sichuan University in China.

Snigdha is a global R&D and Medical Affairs executive with more than 25 years of experience across academic research, pharmaceutical, and consumer healthcare industries. She is recognized for leading scientific, medical, and data-driven strategies that advance product innovation, enable global market expansion, and improve health outcomes through clinical evidence generation and the integration of science and business. She has a strong track record of driving successful product launches, regulatory strategies, and enterprise growth while leading complex global organizations.

Snigdha currently serves as Head of Strategy & Development and Chief of Staff to the CEO at ClinChoice, where she partners with executive leadership to shape corporate strategy and drive global growth initiatives.

Prior to this, she founded Cobble & Thrive LLC, an advisory firm supporting life sciences and consumer health companies on medical and R&D strategy.
Previously, Snigdha served as Senior Vice President of Regulatory Sciences at Juul Labs, where she led global scientific strategy, regulatory evidence generation, and post-market safety, building and overseeing multidisciplinary teams across clinical research, toxicology, epidemiology, and data analytics. She also served as Divisional Vice President of Scientific & Medical Affairs at Abbott Nutrition, leading global clinical development, medical affairs, health economics and outcomes research, and medical safety to support product innovation and commercialization.

Earlier, she held Vice President roles at Reckitt Benckiser, where she led global medical and scientific affairs across multiple consumer health categories and supported business development and Rx-to-OTC switch initiatives. She also held senior leadership positions at Pfizer, Alcon (a Novartis company), and GlaxoSmithKline, leading global medical affairs, clinical research, and lifecycle management programs.

Snigdha holds a PhD in Pharmacology and completed postdoctoral research in molecular genetics and cell signaling.

Jayme Calhoun is the International Head of Regulatory Affairs for ClinChoice. In this role she oversees ClinChoice’s International Regulatory Centers of Excellence to deliver comprehensive regulatory support to clients. Jayme has over 25 years of industry experience spanning from Novel Drugs to Consumer products, with a focus on Medical Device regulations.

Prior to joining ClinChoice, Jayme was Vice President of Regulatory Affairs at a start-up biotechnology company where she created and grew a new regulatory department for initial applications and market expansion of devices, combination products, drugs, and consumer products. Prior to that, she was a Project Manager for a tissue based BLA project overseeing the timely completion of cGMP upgrades and Phase III clinical trials.

Earlier, Jayme spent 8 years with Surgical Specialties (this company is now called Corza Medical)  in Quality and Regulatory roles overseeing corporate regulatory and quality goals for 3 manufacturing facilities, and acting as a regulatory liaison for FDA, Notified Bodies, and PMDA audits. Her prior experience includes roles at Medtronic and GlaxoSmithKline. In addition to serving as a management representative for multiple Heath Authority audits, she has experience supporting international registrations, authoring FDA, Health Canada, and EU submissions, and is respected for her ability to work with regulators from both a quality and regulatory aspect.

Jayme received her Bachelor degree in Chemistry from Connecticut College and her Master of Business Administration degree from the University of Florida. Jayme holds a RAC certification in Medical Devices.

Valerie Perentesis, Pharm. D. is the International Head of Safety & Medical Affairs at ClinChoice Inc. Valerie is a seasoned leader with 25 years of experience in pharmaceutical & consumer R&D.

Valerie started her career in academia as an assistant professor at St John’s University. She then evolved to work as a clinical hospital pharmacist in the NYC area, where she held various positions leading up to Director of Pharmacy Services at Beth Israel Medical Center.

Later, Valerie advanced her career and moved into the pharmaceutical industry. She spent 25+ years in Research and Development at various companies, she started at Pfizer in the Regulatory/Pharmacovigilance Department holding various roles before moving into Portfolio Management at Pfizer where she managed one-third of Pfizer’s R&D portfolio. Before leaving Pfizer Valerie held the position of Compound Development Team Lead Infectious Diseases.

She then moved to BMS and held a variety of pharmacovigilance senior positions and was instrumental in outsourcing pharmacovigilance activities to India. She then moved on to JNJ-Janssen where she led their Global Pharmacovigilance Operations.

Lastly, prior to joining ClinChoice, Valerie headed up Global Pharmacovigilance Operations at Alexion.

She earned her Doctor of Pharmacy degree from the Medical University of South Carolina, her Bachelor’s Degree in Pharmacy from St. John’s University and an ASHP Accredited Residency from The University of California San Francisco.

James Liu, MS, is the International Head of Quality and Strategy at ClinChoice Inc. James is responsible for leading the activities related to the development and implementation of standard operating procedures (SOPs), policies and procedures that ensure quality standards are met throughout the Company. James builds strong relationships with key stakeholders globally ensuring alignment among management team members and legacy entities. James also leads the integration of key systems and processes and participates in strategic planning. James has experience with clinical operations, data management, programming, biostatistical analysis, safety management (pharmacovigilance), and regulatory affairs.

James has been working in the pharmaceutical and CRO industry since 2002. Prior to joining ClinChoice, he held a position at Wyeth/Pfizer as Manager, Analytical Information Systems and before that served as Compliance Specialist/Manager of Electronic Quality Systems at Mutual Pharmaceutical Company, Inc.

Mr. Liu earned his Master of Science degree in Electrical & Computer Engineering as well as Analytical Chemistry from the University of Wisconsin-Madison with his Bachelor of Science degree in Chemistry from Peking (Beijing) University, China.